What a 3-Month PET-CT Can Predict About CAR-T Outcomes in Multiple Myeloma | IMS 2026

Esteban Tamariz-Amador, MD, of Clínica Universidad de Navarra discusses how PET-CT scans can help predict outcomes after CAR-T at IMS 2026 in Glasgow. Drawing on about 75 CAR-T patients treated in Spain and Italy, he explains why disease outside the bone marrow and higher disease volume signal a tougher road, and why the three-month scan is more informative than the one-month scan. He also describes when a bispecific antibody may be a better fit.

If this video has helped you or a loved one, consider donating to HealthTree. Every donation helps us continue to create free and high-quality blood cancer educational content: https://give.healthtree.org/give/628617/src=htu

For an organized lesson structure, watch on our site here: https://linktr.ee/HealthTreeUniversity
Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer!

Patients have the key to find cures for cancer. Learn more about HealthTree's services here: https://healthtree.org/curehub?utm_source=social+media&utm_medium=htu+youtube&utm_campaign=htu-curehub&utm_content=general
Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.

Timestamps:
0:00 Introduction: Dr. Esteban Tamariz-Amador, Clínica Universidad de Navarra
0:18 Why Use PET-CT After CAR-T?
0:48 The Challenge: Predicting Who Relapses
1:19 Study Design: 75 Patients, Three Scans
1:31 What the Scans Showed at Baseline
2:07 Why the Three-Month Scan Is More Informative
2:38 Can CAR-T Clear Extramedullary Disease?
3:01 CAR-T or Bispecifics for Extramedullary Disease?